BACKGROUND: Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV), known as FOLFIRI regimen, has shown activity in recurrent or metastatic colorectal cancer. Therefore, we evaluated the efficacy and safety of irinotecan, 5-FU and a low dose of LV (modified FOLFIRI) as a first line of therapy for patients with relapsed or metastatic colorectal cancer. METHODS: Between January 2002 and October 2004, 44 patients with histologically confirmed recurrent or metastatic colorectal cancer were enrolled. The chemotherapy regimen schedule consisted of 180 mg/m2 of irinotecan being administered intravenously (i.v) on Day 1, 400 mg/m2 of 5-FU via i.v bolus with 600 mg/m2 of continuous infusion for 22 hrs on both Day 1 and 2, and 20 mg/m2 of leucovorin on both Day 1 and 2 , repeated every two weeks. RESULTS: The overall response rate was 47.8%. Of the 40 evaluated patients, one had CR (2.3%) and 20 had PR (46.5%). Toxicities were mild and easily manageable. Three patients experienced 23 episodes of Grade 3/4 leukopenia., Only one patient developed Grade 3/4 diarrhea. None experienced Grade 3/4 thrombocytopenia. CONCLUSION: Modified FOLFIRI with a low dose of LV is an effective and tolerable regimen for patients with recurrent or metastatic colorectal cancer.
BACKGROUND:Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV), known as FOLFIRI regimen, has shown activity in recurrent or metastatic colorectal cancer. Therefore, we evaluated the efficacy and safety of irinotecan, 5-FU and a low dose of LV (modified FOLFIRI) as a first line of therapy for patients with relapsed or metastatic colorectal cancer. METHODS: Between January 2002 and October 2004, 44 patients with histologically confirmed recurrent or metastatic colorectal cancer were enrolled. The chemotherapy regimen schedule consisted of 180 mg/m2 of irinotecan being administered intravenously (i.v) on Day 1, 400 mg/m2 of 5-FU via i.v bolus with 600 mg/m2 of continuous infusion for 22 hrs on both Day 1 and 2, and 20 mg/m2 of leucovorin on both Day 1 and 2 , repeated every two weeks. RESULTS: The overall response rate was 47.8%. Of the 40 evaluated patients, one had CR (2.3%) and 20 had PR (46.5%). Toxicities were mild and easily manageable. Three patients experienced 23 episodes of Grade 3/4 leukopenia., Only one patient developed Grade 3/4 diarrhea. None experienced Grade 3/4 thrombocytopenia. CONCLUSION: Modified FOLFIRI with a low dose of LV is an effective and tolerable regimen for patients with recurrent or metastatic colorectal cancer.
Authors: M Ducreux; M Ychou; J F Seitz; M Bonnay; A Bexon; J P Armand; M Mahjoubi; D Méry-Mignard; P Rougier Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245
Authors: Werner Scheithauer; Gabriela V Kornek; Stefan Brugger; Herbert Ullrich-Pur; Julia Valencak; Markus Raderer; Wolfgang Fiebiger; Erwin Kovats; Fritz Lang; Dieter Depisch Journal: Cancer Invest Date: 2002 Impact factor: 2.176
Authors: K Bouzid; S Khalfallah; J Tujakowski; B Piko; G Purkalne; S Plate; P Padrik; M Serafy; E M Pshevloutsky; B Boussard Journal: Ann Oncol Date: 2003-07 Impact factor: 32.976
Authors: C Carnaghi; L Rimassa; I Garassino; P A Zucali; G Masci; M Fallini; E Morenghi; A Santoro Journal: Ann Oncol Date: 2002-09 Impact factor: 32.976
Authors: Andreas Teufel; Silke Steinmann; Jürgen Siebler; Christiane Zanke; Herbert Hohl; Bernd Adami; M Schroeder; O Klein; Thomas Höhler; Peter R Galle; Michael Heike; Markus Moehler Journal: BMC Cancer Date: 2004-07-20 Impact factor: 4.430